Nektar Therapeutics (NKTR) Q2 FY26 earnings call

Nektar Therapeutics is advancing its lead asset, REZPEG, with the initiation of its global Phase III program in atopic dermatitis and finalized design for a single registrational Phase III study in alopecia areata. The company maintains a strong cash position, extending its runway past key data readouts, and is focused on executing its clinical development strategy for REZPEG, a novel T-reg agonist with pipeline-in-a-product potential. An ongoing litigation trial is noted.